Julie Czerkowicz

595 total citations
14 papers, 337 citations indexed

About

Julie Czerkowicz is a scholar working on Physiology, Molecular Biology and Rheumatology. According to data from OpenAlex, Julie Czerkowicz has authored 14 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 5 papers in Molecular Biology and 3 papers in Rheumatology. Recurrent topics in Julie Czerkowicz's work include Alzheimer's disease research and treatments (10 papers), Computational Drug Discovery Methods (3 papers) and Systemic Lupus Erythematosus Research (3 papers). Julie Czerkowicz is often cited by papers focused on Alzheimer's disease research and treatments (10 papers), Computational Drug Discovery Methods (3 papers) and Systemic Lupus Erythematosus Research (3 papers). Julie Czerkowicz collaborates with scholars based in United States, Belgium and Netherlands. Julie Czerkowicz's co-authors include Ann Ranger, Danielle Graham, Dania Rabah, Reneé Shapiro, Kevin L. Otipoby, Frederick R. Taylor, Hannah M. Kerns, Thomas O. Cameron, Joanne L. Viney and Alex Pellerin and has published in prestigious journals such as PLoS ONE, Annals of the Rheumatic Diseases and Neurobiology of Disease.

In The Last Decade

Julie Czerkowicz

14 papers receiving 332 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie Czerkowicz United States	7	135	121	88	63	59	14	337
Sarah E. Heuer United States	9	98 0.7×	46 0.4×	56 0.6×	72 1.1×	89 1.5×	21	295
Marzena J. Fabis‐Pedrini Australia	10	35 0.3×	148 1.2×	29 0.3×	30 0.5×	78 1.3×	24	318
Panagiota Davaki Greece	12	93 0.7×	38 0.3×	32 0.4×	49 0.8×	96 1.6×	22	315
Carmen Picón Spain	10	86 0.6×	142 1.2×	28 0.3×	163 2.6×	167 2.8×	15	510
Rainer Akkermann Germany	11	69 0.5×	175 1.4×	20 0.2×	77 1.2×	131 2.2×	14	439
Maximilian Deußing Germany	8	120 0.9×	103 0.9×	10 0.1×	190 3.0×	66 1.1×	24	344
Silvana Montella Italy	8	38 0.3×	162 1.3×	38 0.4×	23 0.4×	61 1.0×	13	409
Miriam Baca United States	5	69 0.5×	47 0.4×	48 0.5×	13 0.2×	79 1.3×	6	234
Lori Lebson United States	8	149 1.1×	129 1.1×	13 0.1×	172 2.7×	148 2.5×	15	436
Susanna M. Grzeschik United States	10	56 0.4×	33 0.3×	28 0.3×	53 0.8×	221 3.7×	14	545

Countries citing papers authored by Julie Czerkowicz

Since Specialization

Citations

This map shows the geographic impact of Julie Czerkowicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Czerkowicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Czerkowicz more than expected).

Fields of papers citing papers by Julie Czerkowicz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Czerkowicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Czerkowicz. The network helps show where Julie Czerkowicz may publish in the future.

Co-authorship network of co-authors of Julie Czerkowicz

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Czerkowicz. A scholar is included among the top collaborators of Julie Czerkowicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Czerkowicz. Julie Czerkowicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Shulman, Melanie, Jessica Kong, John O’Gorman, et al.. (2023). TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease. Nature Aging. 3(12). 1591–1601. 47 indexed citations

Vanbrabant, Jeroen, Steffi De Meyer, Carrie E. Rubel, et al.. (2023). Performance of plasma pTau181 and pTau217 measured with fully automated LUMIPULSE G prototype immunoassays. Alzheimer s & Dementia. 19(S15). 1 indexed citations

Vanbrabant, Jeroen, Sherif Bayoumy, Inge M.W. Verberk, et al.. (2023). Performance of optimized prototype LUMIPULSE G immunoassays for plasma pTau181 and pTau217. Alzheimer s & Dementia. 19(S24). 2 indexed citations

Kivisäkk, Pia, Becky C. Carlyle, James P. Quinn, et al.. (2022). Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease. Alzheimer s Research & Therapy. 14(1). 58–58. 54 indexed citations

Kivisäkk, Pia, Becky C. Carlyle, Bianca A. Trombetta, et al.. (2021). Levels of the synaptic proteins PSD‐95, SNAP‐25, and neurogranin are selectively increased in the cerebrospinal fluid of patients with Alzheimer’s disease. Alzheimer s & Dementia. 17(S5). 1 indexed citations

Vanbrabant, Jeroen, Erik Stoops, Kimberley Mauroo, et al.. (2021). Development and analytical characterization of novel tau Simoa assays targeting full‐length tau in CSF and mid‐tau in CSF and plasma. Alzheimer s & Dementia. 17(S5). 1 indexed citations

Sopko, Richelle, Olga Golonzhka, Joseph W. Arndt, et al.. (2020). Characterization of tau binding by gosuranemab. Neurobiology of Disease. 146. 105120–105120. 44 indexed citations

Czerkowicz, Julie, Weiping Chen, Kubra Kamisoglu, et al.. (2019). P4‐038: PHARMACOKINETIC AND TARGET ENGAGEMENT (TE) ANALYSIS OF ANTI‐TAU ANTIBODY BIIB092 IN CYNOMOLGUS MONKEYS CNS FLUID COMPARTMENTS. Alzheimer s & Dementia. 15(7S_Part_24). 2 indexed citations

Czerkowicz, Julie, Weiping Chen, Andrew Cameron, et al.. (2018). P4‐021: ANTI‐TAU ANTIBODY BIIB092 BINDS SECRETED TAU IN PRECLINICAL MODELS AND ALZHEIMER'S DISEASE CEREBROSPINAL FLUID. Alzheimer s & Dementia. 14(7S_Part_27). 4 indexed citations

10.

Czerkowicz, Julie, Weiping Chen, Qin Wang, et al.. (2017). [P4–039]: PAN‐TAU ANTIBODY BIIB076 EXHIBITS PROMISING SAFETY AND BIOMARKER PROFILE IN CYNOMOLGUS MONKEY TOXICITY STUDY. Alzheimer s & Dementia. 13(7S_Part_26). 20 indexed citations

11.

Pellerin, Alex, Karel Otero, Julie Czerkowicz, et al.. (2015). Anti‐ BDCA 2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc‐dependent and Fc‐independent mechanisms. EMBO Molecular Medicine. 7(4). 464–476. 92 indexed citations

12.

Biénkowska, Jadwiga, Julie Czerkowicz, Norm Allaire, et al.. (2015). BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. Lupus Science & Medicine. 2(1). e000063–e000063. 34 indexed citations

13.

Fang, Hong, Jadwiga Biénkowska, Julie Czerkowicz, et al.. (2015). A6.44 Only BAFF mRNA, not BAFF protein level in blood, is associated with SLE activity over one year. Annals of the Rheumatic Diseases. 74. A74–A74. 3 indexed citations

14.

Edwards, Keith R., Jaya Goyal, Tatiana Plavina, et al.. (2013). Feasibility of the Use of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis. PLoS ONE. 8(11). e81007–e81007. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact